**Manuscript title**
Non-reproducibility of wearable accelerometer methods in protective association between physical activity and cardiovascular disease: a cohort study.

**Authors**
Yacine Lapointe[a]
Aayush Kapur[a]
Abhinav Sharma[b]
Janna Panter[c]
Daniel Fuller[d]
Hiroshi Mamiya[a]

[a] Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Canada. Suite 1200, 2100 McGill College, Montreal, QC, Canada,
H3A 1G1

[b] Department of Medicine, Research Institute of the McGill University Health Centre, McGill University, Canada. 1001 Decarie Boulevard, Montreal, QC, H4A 3JZ, Canada

[c] MRC Epidemiology Unit, University of Cambridge, United Kingdom. Box 285 Cambridge, UK, CB2 0QQ

[d] Department of Community Health and Epidemiology, University of Saskatchewan, Canada. Box 7, Health Science Building, 107 Wiggins Road
Saskatoon, SK, Canada, S7N 5E5

**Corresponding author**
Hiroshi Mamiya, Suite 1200, 2100 McGill College, Montreal, Quebec, Canada,
H3A 1G1
hiroshi.mamiya@mcgill.ca

**Manuscript word count**
2,884

**Abstract word count**
298

**Number of references**
35

**Type of manuscript**
Original Research Article

**Abstract**

**Background:** The selection of accelerometer processing methods may influence the shape of the dose-response association between wearable-measured physical activity and health outcomes. We compared the association of stroke and myocardial infarction with Moderate-Vigorous Physical Activity (MVPA) assessed by three accelerometer-generated metrics: modified Euclidean Norm Minus One (ENMO), Machine learning (ML), and activity counts.

**Methods:** We computed MVPA durations in the UK Biobank accelerometer sub-cohort between 2013 and 2015. The outcomes, incident stroke and myocardial infarction, were followed up until December 2022. We used Cox regression and a restricted cubic spline to estimate the dose-response association for each of the three MVPA metrics.

**Results:** There were 90,237 cardiovascular disease-free participants at baseline. We observed 1,298 incident strokes and 2,031 myocardial infarctions. For stroke, a linear decrease in hazard ratio was observed with ML, but not with ENMO and activity counts. For myocardial infarction, ML and ENMO showed a curvilinear decrease in hazard ratios, whereas activity counts showed a linear decrease.

**Conclusion:** The dose-response associations between MVPA and cardiovascular disease varied markedly across the three accelerometer-derived MVPA metrics. Research using a single accelerometer metric may caution about the interpretation of the association.

**Keywords**
Dose-response association, physical activity, cardiovascular diseases, wearable device, machine learning, survival analysis

## Background

Insufficient Physical Activity (PA) is the major risk factor for Cardiovascular Disease (CVD)(1–3). The national and international PA guidelines recommend engaging in greater than 150 minutes/week of Moderate to Vigorous Physical Activity (MVPA) (4,5). MVPA is the intensity of PA enough to elevate the heart rate, including brisk walking (moderate PA) and running (vigorous PA) (6). While meeting the recommendation is linked to a substantial reduction in CVD-related incidence, nearly 29% of males and 34% of females failed to meet this recommendation globally (7).

A meaningful reduction in the risk of CVD may occur well below the 150 minutes/week threshold of MVPA, with the benefit starting as low as 60 minutes/week (8). Accurate characterization of the dose-response association between CVD and PA is critical to assess the population burden of insufficient PA, model the reduction in CVD by shifting population levels of PA, and provide refined recommendations for PA. Existing meta-analyses agree on the incomplete understanding of the dose-response association due to the inaccuracy of PA measures by self-report (9,10). Recent studies using wearable-derived PA suggest either a curvilinear or linear reduction of CVD risk as the duration of MVPA increases, with varying slopes and plateaus of risk reduction (11–13).

There are numerous approaches to convert device-generated accelerometer data into PA intensity and duration to estimate MVPA, with varying levels of accuracy to identify MVPA (19–21). Researchers commonly compute continuous values of summary metrics within a discrete time window called an epoch from accelerometer data (14,15). These summary metrics can be

computed from raw tri-axial (x/y/z-axes) accelerometer signals, including a widely used Euclidean Norm Minus One (ENMO) (16). Other summary metrics constitute manufacturers' proprietary metrics, such as activity counts computed from triaxial or single-axis (y-axis) accelerometer signals (17). These summary values are often discretized into relevant intensity categories, such as MVPA, light PA, and sedentary activity, at the epoch level, before aggregating to obtain the total time spent in each intensity category. Such categorization is typically based on pre-defined thresholds or 'cut-points' derived from calibration studies utilizing ground-truth data specific to cohort characteristics, such as age and device wear locations (e.g., hip and wrist) (14,18). There are also methods that do not rely on pre-determined cut-points, including Machine Learning (ML). ML can estimate activity intensity at each epoch using numerous predictive feature variables derived from raw accelerometer data or summary metrics (e.g., activity counts) (17,19).

The selection of accelerometer methods influences study results. Comparison studies showed large discrepancies in the prevalence of meeting the PA guidelines within the same populations due to the widely varying accuracy of these methods to quantify MVPA (14,20). In terms of etiology, there is limited knowledge about how decisions in selecting accelerometer methods influence dose-response associations between wearable-derived PA and health outcomes. Such knowledge will help explain the heterogeneity in dose-response associations and promote the standardization and harmonization of derived PA (20).

The objective of this study is to compare dose-response associations between CVD (incident stroke and myocardial infarction) across three distinct accelerometer metrics of MVPA from the

UK Biobank accelerometer cohort. These are modified Euclidean Norm Minus One (ENMO), ML, and activity count-based metrics, with the first and third metrics using previously reported intensity cut-points for MVPA.

## Methods and data

### *Sample*

This is a longitudinal (time-to-event) study. UK Biobank is a prospective cohort study collecting biomedical data from over 500,000 participants aged 40-69 since the baseline assessment in 2006. Our study population is the UK Biobank accelerometer sub-cohort, consisting of 103,686 consented to wear wearable devices for seven consecutive days between 2013 and 2014 (21). Individuals meeting the definition of insufficient wear time (less than 72 consecutive hours) were excluded (21). We also excluded individuals who had a stroke or myocardial infarction before the accelerometer data collection period. We also removed those missing baseline covariates, e.g., diets, income, education, and smoking, whose proportion in the cohort was far less than 5% (flowchart in Supplementary eFigure 1).

*Accelerometer metrics*In UK Biobank, wrist-worn Axivity Ax3 (Axivity, United Kingdom) generated raw tri-axial accelerometer data for seven consecutive days. The data were previously processed by calibrating signals to local gravity, removing infeasible accelerometer levels, imputing non-wear time, computing the vector magnitude (i.e., Euclidean Norm) from the triaxial data, and applying a Butterworth low-pass filter to remove noise (21). The resulting 5-second (epoch) summary of vector-magnitude acceleration minus one gravitational unit, as made available in UK Biobank, represents a modified version of ENMO (hereafter called ENMO)

(16,21). To compute the time spent on MVPA for each participant in minutes/week, we applied a commonly used and validated cut-point of 100mg to classify MVPA for ENMO (18).

For ML, we used the derived duration of MVPA records by a previously reported ML model using UK Biobank, which combines a random forest and a hidden Markov model (22). The model was previously trained on predictive features from raw accelerometer data at 30-second epochs aligned with ground truth data from 151 participants' 24-hour activity data called Capture-24 (23). Previous studies already used this ML model to estimate the association of PA with CVD using UK Biobank, albeit focusing on the compositional exposure (24-hour activity) or combination with bouts, rather than MVPA and/or with a shorter follow-up time ending in 2021 than our study, extending to the end of 2022 (11,22,23).

For activity counts, we applied open-source data processing methods to reproduce device manufacturer-proprietary activity counts at 30-second epoch resolution from raw accelerometer data after the pre-processing steps described above (24,25). We then used cut-points for wrist-worn devices validated against free-living adult participants (15). These are <2,860 CPM (Counts Per Minute) for sedentary, 2,860-3,940 CPM for LPA, and ≥ 3,941 CPM for MVPA, multiplied by 0.5 seconds for our 30-second epoch.

The two outcomes are the first episode of stroke and myocardial infarction (both fatal and non-fatal), both of which are ascertained by the UK Biobank's adjudicated algorithms integrating hospital episodes, death certificates, and self-reports (26). Follow-up of participants began after the collection of accelerometer data (between 2013-2014, depending on participants) and

continued until death, diagnosis of first stroke or myocardial infarction, or the end of the last available date in the hospital and death records on November 30, 2022.

*Statistical analysis*

For descriptive analysis, we compared the agreement between the three derived weekly MVPA durations and the ground-truth MVPA durations using scatterplots and Spearman's rank correlation in 151 participants from the Capture-24 validation study. We used the *Accelerometer* Python library and leave-one-out cross-validation to generate a prediction by ML among this validation sample (27). For dose-response analysis, we used Cox regression to model the time to stroke and myocardial infarction separately, with time measured in months since the accelerometer assessment. To account for non-linear associations, we used a restricted cubic spline function with its knots placed at the $5^{th}$ , $50^{th}$, and $95^{th}$ percentiles of the data (28). We evaluated the number of knots and the linearity (use of the spline or not) based on Akaike's Information Criterion. We used Schoenfeld residuals to evaluate the proportional hazards assumption.

We added potential confounder variables, including age on a continuous scale and sex, education, and income as categorical variables. We also added self-reported consumption of tobacco smoking, alcohol consumption, red meat, fruits, vegetables, and oily and non-oily fish, all on a categorical scale (11,22). We also controlled for racialized identity, dichotomized into visible minorities (Asian or Asian British, Black or Black British, and other non-White races) vs. White, due to the limited proportion of identities in each non-White group. The categorization of these variables was already defined by UK Biobank (Table 1).

We added several sensitivity analyses. First, we added the self-reported MVPA duration collected by the International Physical Activity Questionnaire. Second, we characterized sex-specific dose-response relationships to assess heterogeneity in protective associations. Third, we excluded cases that developed CVD outcomes within 2 years of accelerometer assessment to assess the presence of reverse causation. Fourth, we performed re-analyses that included type 2 diabetes mellitus, BMI, self-reported depression, and self-reported health status, which we did not include in the main analysis, as they may mediate the association between PA and CVD. Fifth, we added clinical markers of CVD, which may also serve as mediators rather than confounders. They are systolic and diastolic blood pressure, triglycerides, C-reactive protein, Hemoglobin A1c, high- and low-density lipoprotein, and the use of antiplatelet, antihypertensive, and lipid-lowering medications. Finally, we also performed a competing risks analysis to account for the potential impact of non-CVD deaths that would have precluded our outcome events.

Software codes are publicly available (29). The study was approved by the Faculty of Medicine Institutional Review Board (A08-M55-24A). We provided the Strengthening the Reporting of Observational studies in Epidemiology checklist (Supplementary File 2).

**Results**

There were 2,016 and 1,282 incidences of first stroke and myocardial infarction before December 2022, respectively (Table 1). The median follow-up was 96.9 months (Interquartile Range [IQR]: 89.7-102.7) for CVD-free participants, and 47.2 (IQR: 17.2-72.9) for cases. Participants without CVD showed longer median MVPA durations, tended to be female and

never smokers, had higher levels of education and income, and showed lower consumption of processed and red meat.

Histograms of weekly MVPA duration showed varying skewness across the three metrics (Figure 1A-C). The median duration was the largest for the activity count-based metric (585.9 minutes/week, IQR: 372.1-853.2) and the smallest for ML (234.1 minutes/week, IQR: 114.5-404.0). The agreement between the ground truth and the three MVPA metrics varied substantially (Figure 2A-C). The corresponding Spearman's correlations are 0.50, 0.78 and 0.37 for ENMO, ML, and activity counts, respectively.

The confounder-adjusted dose-response associations are shown in Figure 3A-F. The plots display the associations up to 1,500 minutes per week of MVPA, since observations beyond this duration are sparse, as indicated by the density of observations at the bottom of each plot, which would have resulted in a wide 95% Confidence interval (CI). The unadjusted associations (Supplementary eFigure 2A-F) showed similar dose-response shapes to the adjusted associations, although the magnitude of the protective associations (reduction in Hazard Ratio [HR]) was more pronounced.

The shapes of association for each outcome varied across the three metrics but were generally linear or curvilinear. For ENMO, the association plateaued at approximately 650 minutes/week of MVPA of the inflection point for both outcomes (Figures 3A and 3B for stroke and myocardial infarction, respectively). For ML, the protective association was linear: the model without spline showed a better model fit according to Akaike's Information Criterion (Figure 3C). For myocardial infarction, ML showed a curvilinear association with a very modestly increased HR

after the inflection point at approximately 400 minutes/week of MVPA, i.e., *J-shape* (Figure 3D). However, this increased trend is inconclusive given the width of the 95% CI. For activity counts, the estimated curvilinear association with stroke is similar to that of ENMO, but the inflection point was slightly larger at approximately 800 minutes/week (Figure 3E). For myocardial infarction, activity counts showed a linear association, unlike ENMO and ML (Figure 3F). Regarding the magnitude of the protective effect, ENMO showed the strongest reduction of HR down to approximately HR = 0.37 in both outcomes.

In our sensitivity analyses, self-reported MVPA showed shorter weekly MVPA durations than those reported by the ENMO and activity counts (Supplementary eFigure 3). The dose-response associations based on self-reported MVPA showed a much weaker protective effect for stroke and myocardial infarction (Supplementary eFigures 4A and 4B, respectively). For the sex-specific analysis of stroke, the shape of association was similar between females (Supplementary eFigures5-7 A, green shade) and males (Supplementary eFigures 5-7 C, grey shade) for all three derived measures (Supplementary eFigures 5, 6, and 7 for ENMO, ML, and activity count, respectively). However, the protective association was slightly stronger (with slightly lower HR values) for males. For myocardial infarction, females had distinct shapes of associations with a more pronounced and linear decrease in HR, compared to the male subsample with curvilinear associations, for all three measures (contrast of supplementary eFigures 5-7 B for females vs. eFigures 5-7 D for males). The exclusion of participants who developed the outcomes within 2 years of the exposure assessment did not yield noticeable changes (Supplementary eFigure 8). The associations remained robust after accounting for potential mediators (BMI, depression, and type 2 diabetes mellitus) and clinical markers of CVD, as well as medications (Supplementary eFigures 9 and 10). Finally, competing risk analysis showed a more pronounced protective effect

of MVPA for both stroke and myocardial infarction (Supplementary eFigure 11). However, the overall shape of the associations for all MVPA metrics remained very similar.

**Discussion**

We investigated the non-reproducibility of dose-response associations between MVPA and CVD across three MVPA metrics from accelerometer data using the UK Biobank accelerometer sub-cohort. The three derived metrics exhibited varying agreement with the ground-truth data. They also showed distinct shapes of dose-response associations with stroke and myocardial infarction.

Descriptive analysis indicates that ML has the lowest measurement error relative to the ground truth, followed by ENMO, while activity counts showed the least agreement. The finding is consistent with previous studies (15,19,22). ENMO and activity counts may report a higher duration of MVPA than ML, as seen in this study, when applied to noisy data from free-living participants (30). Self-reported measures from the sensitivity analysis yielded a far shorter duration of MVPA than ENMO and activity count, potentially because the questionnaire excludes activities without a minimum of 10 minutes of bouts (31,32). In our data, all three accelerometer-derived metrics led most participants to achieve more than 150 minutes/week of MVPA, the guideline originally developed from self-reports.

The three metrics agreed that the increase in MVPA incrementally reduces the risk of both outcomes even when the duration was well below the recommended 150 minutes/week cutoff, consistent with previous meta-analyses (8–10). However, we highlight that the shape of the associations (steepness and plateau point) varies noticeably across metrics. Specifically, only the

ML-derived MVPA showed a linear decrease of HR for stroke (as opposed to the curvilinear associations for ENMO and activity counts). For myocardial infarction, only activity counts showed a linear association. These results indicate that the methodological decision for accelerometer processing methods can partly explain the inconsistency of dose-response associations. We thus suggest careful interpretation of dose-response associations estimated in studies using a single processing method.

Since ML showed the best agreement with the ground truth, it might yield the most unbiased estimate of the dose-response association. However, ML requires ground truth (i.e., labelled) data within each epidemiologic cohort, which are not always available due to the cost of recording and annotating image data from free-living participants, in addition to respondent burden (33). Cut-point approaches combined with accelerometer summary metrics (e.g., activity counts and ENMO utilizing externally developed intensity thresholds) do not require internal ground-truth data; however, they showed a lower agreement with the ground truth in our and other studies; hence supporting calls to utilize ML or move away from cut-point (discretization) approaches in favour of continuous metrics such as average acceleration (19,30).

Our sensitivity analysis indicates that the protective associations estimated from self-reported MVPA are considerably smaller than those from device-derived MVPA metrics, consistent with a previous study using the UK Biobank (11). For the female subsample, the greater protective effect of MVPA for myocardial infarction, as agreed by all three metrics, is consistent with a previous study (9). However, we did not observe any female-specific benefit in stroke outcome, again agreed by all metrics.

The strengths of this study include comparing three accelerometer processing metrics to address the unexplored discrepancy in dose-response etiologic associations. This is a novel addition to the literature, which to date has focused on comparing the prevalence of physical activity across accelerometer processing methods, especially among children, rather than on etiologic dose-response associations among adults (20,34). The limitations include the UK Biobank's lack of representativeness of the UK population, since the sampling is participant-driven. Nevertheless, a previously reported association between meeting the physical activity guideline and CVD incidence did not differ statistically before and after post-stratification, suggesting the absence of selection bias (35). Also, we did not assess variation of associations due to other influential factors, such as wearable device types (e.g., Axivity v.s. ActiGraph), size of epoch, the value of intensity thresholds (e.g., use of 125mg instead of 100mg for ENMO), type of vector magnitude summary (e.g, Monitor-Independent Movement Summary - MIMS, instead of ENMO), and location of device e.g., hip vs wrist, all of which contribute to the variation of findings (14,15,30).

Thus, future work should include a more comprehensive comparison of etiologic associations across these methodological factors. Such comparison studies should ideally include various ML algorithms trained by data from free-living participants, given ML's superior accuracy over cut-point methods (19,30). Another research avenue is to investigate dose-response associations for other PA intensities, including light PA, total PA (combination of light and MVPA), and sedentary behaviour. Finally, studies to calibrate dose-response associations using measurement error models and non-linear survival analysis, incorporating ground-truth (internal validation)

data, should be conducted (8). This is because even the ML model showed substantial measurement error in our study, which should be accounted for.

In conclusion, we demonstrated that the selection of accelerometer processing methods for MVPA can influence the dose-response association between MVPA and CVD outcomes. Thus, when characterizing the benefits of MVPA for CVD prevention, researchers should exercise caution in interpreting findings from a single MVPA measure.

**Data availability statement**

UK Biobank data are available for research upon approval from the UK Biobank Access Management System.

**Description of conflicts of interest**

Sharma has received research support from Roche Diagnostics, Boehringer Ingelheim, Novartis, Janssen, Novo Nordisk, Servier, AstraZeneca, and Takeda. Also, Sharma has equity stake and/or has co-founded: AREA19, Aerocardia, Perc-assist.

**Declaration of generative AI in scientific writing**
We did not use generative AI in any stage of manuscript preparation.

**Source of funding**
McGill University, Faculty of Medicine.

**Glossary**
Euclidean Norm Minus One, Moderate-Vigorous Physical Activity

**Acknowledgements**
We appreciate Dr. Shing Chan and Dr. Aiden Doherty for their helpful comments on the Capture-24 dataset and the Accelerometer Python library.

## References


1. Global Burden of Diseases, 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021 Oct;20(10):795–820.

2. Warburton D, Bredin S. Health benefits of physical activity: a systematic review of current systematic reviews. Curr Opin Cardiol. 2017 Sept;32(5):541.

3. WHO. WHO guidelines on physical activity and sedentary behaviour [Internet]. 2020 [cited 2024 Feb 3]. Available from: https://www.who.int/publications-detail-redirect/9789240015128

4. Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020 Dec;54(24):1451–62.

5. Statistics Canada. Canadian Health Measures Survey: Activity monitor data, 2018-2019 [Internet]. 2021 [cited 2024 Mar 5]. Available from: https://www150.statcan.gc.ca/n1/daily-quotidien/210901/dq210901c-eng.htm

6. Canadian Society for Exercise Physiology. Glossary – 24-Hour Movement Guidelines [Internet]. [cited 2025 Feb 12]. Available from: https://csepguidelines.ca/resources/glossary/

7. Strain T, Flaxman S, Guthold R, Semenova E, Cowan M, Riley LM, et al. National, regional, and global trends in insufficient physical activity among adults from 2000 to 2022: a pooled analysis of 507 population-based surveys with 5·7 million participants. Lancet Glob Health. 2024 Aug;12(8):e1232–43.

8. Kazemi A, Soltani S, Aune D, Hosseini E, Mokhtari Z, Hassanzadeh Z, et al. Leisure-time and occupational physical activity and risk of cardiovascular disease incidence: a systematic-review and dose-response meta-analysis of prospective cohort studies. Int J Behav Nutr Phys Act. 2024 Apr 24;21(1):45.

9. Garcia L, Pearce M, Abbas A, Mok A, Strain T, Ali S, et al. Non-occupational physical activity and risk of cardiovascular disease, cancer and mortality outcomes: a dose–response meta-analysis of large prospective studies. Br J Sports Med. 2023 Aug 1;57(15):979–89.

10. Chen Y, Jin X, Chen G, Wang R, Tian H. Dose-Response Relationship Between Physical Activity and the Morbidity and Mortality of Cardiovascular Disease Among Individuals With Diabetes: Meta-Analysis of Prospective Cohort Studies. JMIR Public Health Surveill. 2024 Aug 19;10(1):e54318.

11. Watts EL, Saint-Maurice PF, Doherty A, Fensom GK, Freeman JR, Gorzelitz JS, et al. Association of accelerometer-measured physical activity level with risks of hospitalization for 25 common health conditions in uk adults. JAMA Netw Open. 2023 Feb 16;6(2):e2256186.

12. Ahmadi MN, Hamer M, Gill JMR, Murphy M, Sanders JP, Doherty A, et al. Brief bouts of device-measured intermittent lifestyle physical activity and its association with major adverse cardiovascular events and mortality in people who do not exercise: a prospective cohort study. Lancet Public Health. 2023 Oct 1;8(10):e800–10.

13. Ekelund U, Tarp J, Steene-Johannessen J, Hansen BH, Jefferis B, Fagerland MW, et al. Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis. BMJ. 2019 Aug 21;366:l4570.

14. Migueles JH, Cadenas-Sanchez C, Tudor-Locke C, Löf M, Esteban-Cornejo I, Molina-Garcia P, et al. Comparability of published cut-points for the assessment of physical activity: Implications for data harmonization. Scand J Med Sci Sports. 2019 Apr;29(4):566–74.

15. Montoye AHK, Clevenger KA, Pfeiffer KA, Nelson MB, Bock JM, Imboden MT, et al. Development of cut-points for determining activity intensity from a wrist-worn ActiGraph accelerometer in free-living adults. J Sports Sci. 2020 Nov;38(22):2569–78.

16. Hees VT van, Gorzelniak L, León ECD, Eder M, Pias M, Taherian S, et al. Separating Movement and Gravity Components in an Acceleration Signal and Implications for the Assessment of Human Daily Physical Activity. PLOS ONE. 2013 Apr 23;8(4):e61691.

17. Lyden K, Keadle SK, Staudenmayer J, Freedson PS. A Method to Estimate Free-Living Active and Sedentary Behavior from an Accelerometer. Med Sci Sports Exerc. 2014 Feb;46(2):386.

18. Hildebrand M, VAN Hees VT, Hansen BH, Ekelund U. Age group comparability of raw accelerometer output from wrist- and hip-worn monitors. Med Sci Sports Exerc. 2014 Sept;46(9):1816–24.

19. Narayanan A, Desai F, Stewart T, Duncan S, Mackay L. Application of raw accelerometer data and machine-learning techniques to characterize human movement behavior: a systematic scoping review. J Phys Act Health. 2020 Mar 1;17(3):360–83.

20. Phillips SM, Clevenger KA, Bruijns BA, Tucker P, Vanderloo LM, Loh A, et al. Effect of Accelerometer Cut-Points on Preschoolers' Physical Activity and Sedentary Time: A Systematic Review and Meta-Analysis. 2024 Sept 3 [cited 2025 Dec 31]; Available from: https://journals.humankinetics.com/view/journals/jmpb/7/1/article-jmpb.2023-0060.xml

21. Doherty A, Jackson D, Hammerla N, Plötz T, Olivier P, Granat MH, et al. Large scale population assessment of physical activity using wrist worn accelerometers: the uk biobank study. PLoS ONE. 2017 Feb 1;12(2):e0169649.

22. Walmsley R, Chan S, Smith-Byrne K, Ramakrishnan R, Woodward M, Rahimi K, et al. Reallocation of time between device-measured movement behaviours and risk of incident cardiovascular disease. Br J Sports Med. 2022 Sept;56(18):1008–17.

23. Chan S, Yuan H, Tong C, Acquah A, Schonfeldt A, Gershuny J, et al. CAPTURE-24: A large dataset of wrist-worn activity tracker data collected in the wild for human activity recognition [Internet]. arXiv; 2024 [cited 2024 July 22]. Available from: http://arxiv.org/abs/2402.19229

24. Ruben Brondeel. ActigraphCounts: Generating ActiGraph Counts from Raw Acceleration Recorded by an Alternative Monitor [Internet]. 2019 [cited 2025 Jan 21]. Available from: https://github.com/jbrond/ActigraphCounts/tree/master

25. Yu Guan, Dan Jackson, Karim Ladha, Tom Nappey, Patrick Olivier. Openmovement Software [Internet]. 2018 [cited 2025 Jan 21]. Available from: https://github.com/openmovementproject/openmovement/blob/master/Software/AX3/cwa-convert/c/README.md

26. Raisi-Estabragh Z, Petersen SE. Cardiovascular research highlights from the UK Biobank: opportunities and challenges. Cardiovasc Res. 2020 Jan 1;116(1):e12–5.

27. Doherty A, Chang S. Acceleromter Python LIbrary [Internet]. Oxford Wearables Group; 2018 [cited 2025 Apr 10]. Available from: https://github.com/OxWearables/capture24

28. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis [Internet]. New York, NY: Springer; 2001 [cited 2025 Jan 20]. (Springer Series in Statistics). Available from: http://link.springer.com/10.1007/978-1-4757-3462-1

29. Mamiya H. Code repository - AcclerometerProcessing [Internet]. 2025 [cited 2025 July 9]. Available from: https://github.com/hiroshimamiya/AcclerometerProcessing

30. Kerr J, Marinac CR, Ellis K, Godbole S, Hipp A, Glanz K, et al. Comparison of Accelerometry Methods for Estimating Physical Activity. Med Sci Sports Exerc. 2017 Mar;49(3):617–24.

31. Barker J, Smith Byrne K, Doherty A, Foster C, Rahimi K, Ramakrishnan R, et al. Physical activity of UK adults with chronic disease: cross-sectional analysis of accelerometer-measured physical activity in 96 706 UK Biobank participants. Int J Epidemiol. 2019 Aug;48(4):1167–74.

32. Paudel S, Ahmadi M, Phongsavan P, Hamer M, Stamatakis E. Do associations of physical activity and sedentary behaviour with cardiovascular disease and mortality differ across socioeconomic groups? A prospective analysis of device-measured and self-reported UK Biobank data. Br J Sports Med. 2023 July 1;57(14):921–9.

33. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. Am J Epidemiol. 2017 Nov 1;186(9):1026–34.

34. Bourke M, Haddara A, Loh A, Carson V, Breau B, Tucker P. Adherence to the World Health Organization's physical activity recommendation in preschool-aged children: a systematic review and meta-analysis of accelerometer studies. Int J Behav Nutr Phys Act. 2023 Apr 26;20:52.

35. Stamatakis E, Owen KB, Shepherd L, Drayton B, Hamer M, Bauman AE. Is Cohort Representativeness Passé? Poststratified Associations of Lifestyle Risk Factors with Mortality in the UK Biobank. Epidemiology. 2021 Mar;32(2):179.


102,880* participants with accelerometer data tracked
7003 with low-quality accelerometer data,
- Poor calibration = 12
- Insufficient wear time = 6978
- Unrealistically high acceleration values = 13
95,877 participants with high-quality accelerometer data
2936 with diagnosis of stroke or myocardial infarction prior to accelerometer assessment (1140 stroke and 1796 myocardial infarction)
92,941 without previous CVD event
13 Participants lost to follow-up
92,928 not lost to follow-up
2691 missing behavioral risk factors and comorbidities (e.g., diets, smoking, and type II diabetes)
90,237 eligible participants


A
Hazard ratio (stroke)
1.0
0.61
0.37
0.22
0.14
200
600
1000
1400
MVPA (minutes/week)


B
Hazard ratio (stroke)
1.0
0.61
0.37
0.22
0.14
200
600
1000
1400
MVPA (minutes/week)


C
Hazard ratio (stroke)
1.0
0.61
0.37
0.22
0.14
0
200
600
1000
1400
MVPA (minutes/week)


D
Hazard ratio (MI)
1.0
0.61
0.37
0.22
0.14
0
200
600
1000
1400
MVPA (minutes/week)


E
Hazard ratio (MI)
1.0
0.61
0.37
0.22
0.14
200
600
1000
1400
MVPA (minutes/week)


F
Hazard ratio (MI)
1.0
0.61
0.37
0.22
0.14
200
600
1000
1400
MVPA (minutes/week)


15000
10000
5000
0
0
500
1000
1500
2000
Minutes


A
B
1.0
0.61
0.37
0.22
0.14
Hazard ratio (Stroke)
Hazard ratio (MI)
0
500
1000
1500
MVPA (minutes/week)


A
B
C
D
Hazard ratio (Stroke)
Hazard ratio (MI)
1.0
0.61
0.37
0.22
0.14
200
600
1000
1400
MVPA (minutes/week)


A
B
C
D
Hazard ratio (Stroke)
Hazard ratio (MI)
1.0
0.61
0.37
0.22
0.14
0
200
600
1000
1400
MVPA (minutes/week)


A
B
C
D
Hazard ratio (Stroke)
Hazard ratio (MI)
1.0
0.61
0.37
0.22
0.14
200
600
1000
1400
MVPA (minutes/week)


A
Hazard ratio (stroke)
1.0
0.61
0.37
0.22
0.14
200
600
1000
1400
MVPA (minutes/week)


B
Hazard ratio (MI)
1.0
0.61
0.37
0.22
0.14
200
600
1000
1400
MVPA (minutes/week)


C
Hazard ratio (stroke)
1.0
0.61
0.37
0.22
0.14
0
200
600
1000
1400
MVPA (minutes/week)


D
Hazard ratio (MI)
1.0
0.61
0.37
0.22
0.14
0
200
600
1000
1400
MVPA (minutes/week)


E
Hazard ratio (stroke)
1.0
0.61
0.37
0.22
0.14
200
600
1000
1400
MVPA (minutes/week)


F
Hazard ratio (MI)
1.0
0.61
0.37
0.22
0.14
200
600
1000
1400
MVPA (minutes/week)


A
Hazard ratio (stroke)
1.0
0.61
0.37
0.22
0.14
200
600
1000
1400
MVPA (minutes/week)


B
Hazard ratio (MI)
1.0
0.61
0.37
0.22
0.14
200
600
1000
1400
MVPA (minutes/week)


C
Hazard ratio (stroke)
1.0
0.61
0.37
0.22
0.14
0
200
600
1000
1400
MVPA (minutes/week)


D
Hazard ratio (MI)
1.0
0.61
0.37
0.22
0.14
0
200
600
1000
1400
MVPA (minutes/week)


E
Hazard ratio (stroke)
1.0
0.61
0.37
0.22
0.14
200
600
1000
1400
MVPA (minutes/week)


F
Hazard ratio (MI)
1.0
0.61
0.37
0.22
0.14
200
600
1000
1400
MVPA (minutes/week)


A
B
C
D
E
F
Hazard ratio (stroke)
Hazard ratio (MI)
1.0
0.61
0.37
0.22
0.14
0
200
600
1000
1400
MVPA (minutes/week)


A
Hazard ratio (stroke)
1.0
0.8
0.6
0.4
0.2
0.0
0
500
1000
1500
2000
MVPA (minutes/week)
B
Hazard ratio (MI)
1.0
0.8
0.6
0.4
0.2
0.0
0
500
1000
1500
2000
MVPA (minutes/week)
C
Hazard ratio (stroke)
1.0
0.5
0.2
0.1
0
500
1000
1500
2000
MVPA (minutes/week)
D
Hazard ratio (MI)
1.0
0.8
0.6
0.4
0.2
0.0
0
500
1000
1500
2000
MVPA (minutes/week)
E
Hazard ratio (stroke)
1.0
0.8
0.6
0.4
0.2
0.0
0
500
1000
1500
2000
MVPA (minutes/week)
F
Hazard ratio (MI)
1.0
0.5
0.2
0.1
0
500
1000
1500
2000
MVPA (minutes/week)

**Table 1.** Distribution of participant characteristics

| Baseline Characteristics | **CVD**<br>N = 3,298 | **No CVD**<br>N = 86,989 |
|---|---|---|
| Follow up time in months, Median (Q1, Q3) | 47.2 (17.2, 72.9) | 96.9 (90.3, 103.0) |
| MVPA ENMO, Median (Q1, Q3) | 375.8 (236.5, 535.5) | 466.9 (322.6, 644.4) |
| MVPA Machine learning, Median (Q1, Q3) | 196.6 (81.5, 358.0) | 235.1 (116.0, 405.5) |
| MVPA Activity count, Median (Q1, Q3) | 448.9 (268.1, 697.4) | 590.8 (376.7, 857.3) |
| Myocardial infarction, n (%) | 2,016 (63) | 0 (0) |
| Stroke, n (%) | 1,282 (40) | 0 (0) |
| Age, Median (Q1, Q3) | 67.7 (62.7, 71.5) | 63.0 (55.9, 68.3) |
| Race, n (%) | | |
| Non-white | 83 (2.6) | 2,594 (3.0) |
| White | 3,118 (97) | 84,395 (97) |
| Sex, n (%) | | |
| Female | 1,200 (37) | 50,485 (58) |
| Male | 2,001 (63) | 36,504 (42) |
| Education, n (%) | | |
| None of the below | 422 (13) | 6,681 (7.7) |
| O levels/GCSEs or equivalent, CSEs or equivalent | 786 (25) | 21,315 (25) |
| A levels/AS, NVQ/HND/HNC or equivalent | 822 (26) | 20,486 (24) |
| College or University degree | 1,171 (37) | 38,507 (44) |
| Household income GBP, n (%) | | |
| Less than 18,000 | 620 (19) | 10,948 (13) |
| 18,000 to 30,999 | 818 (26) | 18,831 (22) |
| 31,000 to 51,999 | 819 (26) | 22,832 (26) |

| Baseline Characteristics | **CVD** N = 3,298 | **No CVD** N = 86,989 |
|---|---|---|
| 52,000 to 100,000 | 517 (16) | 20,374 (23) |
| Greater than 100,000 | 117 (3.7) | 5,955 (6.8) |
| Do not know/Prefer not to answer | 310 (9.7) | 8,049 (9.3) |
| Smoking, n (%) | | |
| Never | 1,529 (48) | 50,544 (58) |
| Previously | 1,368 (43) | 30,675 (35) |
| Currently | 304 (9.5) | 5,770 (6.6) |
| Alcohol consumption, n (%) | | |
| Never | 226 (7.1) | 4,728 (5.4) |
| Less than once a week | 637 (20) | 17,593 (20) |
| Once or twice a week | 765 (24) | 21,919 (25) |
| Three or four times a week | 793 (25) | 22,830 (26) |
| Daily or almost daily | 780 (24) | 19,919 (23) |
| Processed meat, n (%) | | |
| Less than 2 times a week | 2,136 (67) | 62,097 (71) |
| 2-4 times a week | 929 (29) | 21,832 (25) |
| More than 4 times a week | 136 (4.2) | 3,060 (3.5) |
| Red meat, n (%) | | |
| Less than 2 times a week | 435 (14) | 15,847 (18) |
| 2-4 times a week | 1,118 (35) | 29,458 (34) |
| More than 4 times a week | 1,648 (51) | 41,684 (48) |
| Oily fish, n (%) | | |
| Less than 2 times a week | 2,525 (79) | 71,962 (83) |
| 2-4 times a week | 646 (20) | 14,336 (16) |
| More than 4 times a week | 30 (0.9) | 691 (0.8) |
| Non-oily fish, n (%) | | |

| Baseline Characteristics | **CVD**<br>N = 3,298 | **No CVD**<br>N = 86,989 |
|---|---|---|
| Less than 2 times a week | 2,685 (84) | 73,810 (85) |
| 2-4 times a week | 504 (16) | 12,767 (15) |
| More than 4 times a week | 12 (0.4) | 412 (0.5) |
| Fresh fruit, n (%) | | |
| Less than 2 servings a day | 1,142 (36) | 28,299 (33) |
| Between 2 and 4 servings a day | 1,833 (57) | 52,183 (60) |
| More than 4 servings a day | 226 (7.1) | 6,507 (7.5) |
| Cooked vegetables, n (%) | | |
| Less than 2 servings a day | 506 (16) | 14,848 (17) |
| Between 2 and 4 servings a day | 2,366 (74) | 64,069 (74) |
| More than 4 servings a day | 329 (10) | 8,072 (9.3) |

Abbreviations: MVPA, Moderate-Vigorous Physical Activity, minutes per week; ENMO, Euclidean Norm Minus One; GCSE, General Certificate of Secondary Education; NVQ, National Vocational Qualifications; HND, Higher National Diploma; HNC, Higher National Certificate; GBP, British pound; Q1, First Quantile; Q3, Third Quantile